Septic Shock - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Septic Shock - Pipeline Review, H1 2016', provides an overview of the Septic Shock pipeline landscape. The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Septic Shock - The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects - The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Septic Shock Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Septic Shock - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Septic Shock Overview 9 Therapeutics Development 10 Pipeline Products for Septic Shock - Overview 10 Pipeline Products for Septic Shock - Comparative Analysis 11 Septic Shock - Therapeutics under Development by Companies 12 Septic Shock - Therapeutics under Investigation by Universities/Institutes 14 Septic Shock - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Septic Shock - Products under Development by Companies 18 Septic Shock - Products under Investigation by Universities/Institutes 19 Septic Shock - Companies Involved in Therapeutics Development 20 Adrenomed AG 20 Ferring International Center S.A. 21 Huons Co., Ltd. 22 InflaRx GmbH 23 Leading BioSciences, Inc. 24 Lixte Biotechnology Holdings, Inc. 25 Noxxon Pharma AG 26 Orion Oyj 27 Peptinov SAS 28 Pharmazz, Inc. 29 Spider Biotech 30 Takeda Pharmaceutical Company Limited 31 ViiV Healthcare Limited 32 XImmune AB 33 Septic Shock - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Target 35 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 adrecizumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AM-12 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BC-1215 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 BMS-936559 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BTZO-2 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 C-10 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Drug for Sepsis and Septic Shock - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 HBN-1 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 HBN-3 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 HBN-4 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 HU-003 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 IFX-1 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 L-257 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 LB-100 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 LB-1148 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 levosimendan - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 NOXD-21 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 PMZ-2010 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 R-190 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 SB-056 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 selepressin - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 SP-14 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 SP-9 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Septic Shock - Recent Pipeline Updates 74 Septic Shock - Dormant Projects 81 Septic Shock - Discontinued Products 83 Septic Shock - Product Development Milestones 84 Featured News & Press Releases 84 Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody 84 Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan 84 Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients 85 Feb 02, 2015: Leading BioSciences Recieves FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock 87 Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 88 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Number of Products under Development for Septic Shock, H1 2016 10 Number of Products under Development for Septic Shock - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Comparative Analysis by Unknown Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Septic Shock - Pipeline by Adrenomed AG, H1 2016 20 Septic Shock - Pipeline by Ferring International Center S.A., H1 2016 21 Septic Shock - Pipeline by Huons Co., Ltd., H1 2016 22 Septic Shock - Pipeline by InflaRx GmbH, H1 2016 23 Septic Shock - Pipeline by Leading BioSciences, Inc., H1 2016 24 Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 25 Septic Shock - Pipeline by Noxxon Pharma AG, H1 2016 26 Septic Shock - Pipeline by Orion Oyj, H1 2016 27 Septic Shock - Pipeline by Peptinov SAS, H1 2016 28 Septic Shock - Pipeline by Pharmazz, Inc., H1 2016 29 Septic Shock - Pipeline by Spider Biotech, H1 2016 30 Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 31 Septic Shock - Pipeline by ViiV Healthcare Limited, H1 2016 32 Septic Shock - Pipeline by XImmune AB, H1 2016 33 Assessment by Monotherapy Products, H1 2016 34 Number of Products by Stage and Target, H1 2016 36 Number of Products by Stage and Mechanism of Action, H1 2016 38 Number of Products by Stage and Route of Administration, H1 2016 40 Number of Products by Stage and Molecule Type, H1 2016 42 Septic Shock Therapeutics - Recent Pipeline Updates, H1 2016 74 Septic Shock - Dormant Projects, H1 2016 81 Septic Shock - Dormant Projects (Contd..1), H1 2016 82 Septic Shock - Discontinued Products, H1 2016 83
List of Figures
Number of Products under Development for Septic Shock, H1 2016 10 Number of Products under Development for Septic Shock - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 34 Number of Products by Top 10 Targets, H1 2016 35 Number of Products by Stage and Top 10 Targets, H1 2016 35 Number of Products by Top 10 Mechanism of Actions, H1 2016 37 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 37 Number of Products by Routes of Administration, H1 2016 39 Number of Products by Stage and Routes of Administration, H1 2016 39 Number of Products by Molecule Types, H1 2016 41 Number of Products by Stage and Molecule Types, H1 2016 41
Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing iRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.